Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$1.23
-$0.01(-0.81%)
―
--
Day’s Range― - ―
52-Week Range$0.64 - $2.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$131.76M
Enterprise Value$123.98M
Total Cash (Recent Filing)$14.56M
Total Debt (Recent Filing)$17.49M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding107,121,670
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.84
Enterprise Value/Gross Profit4.76
Enterprise Value/Ebitda-3.58
Forecast
1Y Price Target
$4.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$31.08M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustainably high gross margins reflect a platform/consumables business with strong unit economics. These margins provide structural profitability potential as instrument placements and consumable utilization scale, allowing operating leverage to translate revenue growth into meaningful profit improvement over time.
Strong Cash Position & Low LeverageA large cash balance and negligible debt materially reduce refinancing risk and give management flexibility to fund operations, product launches, and partner support without immediate dilution. This financial buffer supports multi‑year commercialization efforts and milestone timing variability.
Robust SPL Partner PipelineA deep and growing SPL partner base creates recurring access fees, milestone and royalty potential tied to partner clinical progress. As partners advance into later‑stage trials and commercialization, MaxCyte can realize high‑margin, program‑linked revenue that is durable and scalable over multiple years.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow signals ongoing cash burn that can erode reserves if revenue or milestone timing disappoints. Even with current cash, continued negative cash flow increases the likelihood of future financing or cutbacks, constraining long‑term investment optionality.
Declining Core Revenue TrendA material decline in core revenue, driven by lower instrument placements, consumable usage and license receipts, undermines recurring revenue predictability. Reliance on a small number of large customers and inventory management by partners increases concentration risk and slows organic scaling of consumables.
Persistent Operating Losses And Negative ROEChronic operating losses and negative ROE mean the company is consuming shareholder capital rather than compounding it. Over the medium term, sustained unprofitability pressures equity, limits reinvestment capacity, and makes long‑term value creation contingent on reversing revenue trends and achieving operating leverage.
MaxCyte News
MXCT FAQ
What was MaxCyte (MXCT)’s price range in the past 12 months?
MaxCyte (MXCT) lowest stock price was $0.64 and its highest was $2.37 in the past 12 months.
What is MaxCyte (MXCT)’s market cap?
MaxCyte (MXCT)’s market cap is $131.76M.
When is MaxCyte (MXCT)’s upcoming earnings report date?
MaxCyte (MXCT)’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were MaxCyte (MXCT)’s earnings last quarter?
MaxCyte (MXCT) released its earnings results on May 12, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.076 by $0.036.
Is MaxCyte (MXCT) overvalued?
According to Wall Street analysts MaxCyte (MXCT)’s price is currently Undervalued.
Does MaxCyte (MXCT) pay dividends?
MaxCyte (MXCT) does not currently pay dividends.
What is MaxCyte (MXCT)’s EPS estimate?
MaxCyte (MXCT)’s EPS estimate is -0.09.
How many shares outstanding does MaxCyte (MXCT) have?
MaxCyte (MXCT) has 107,121,670 shares outstanding.
What happened to MaxCyte (MXCT)’s price movement after its last earnings report?
MaxCyte (MXCT) reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.076. Following the earnings report the stock price went up 24.088%.
Which hedge fund is a major shareholder of MaxCyte (MXCT)?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (― Downside)
$4.00 (― Downside)
Hedge Fund Trend
Decreased
By 15.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-22.03%
Trailing 12-Months
Asset Growth
-15.43%
Trailing 12-Months
Company Description
MaxCyte (MXCT)
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic positives — including a strong cash position, meaningful OpEx reductions, a $3.0M SPL milestone in Q1, early product traction (ExPERT DTX and SeQure), and a $10M share repurchase authorization — against near-term commercial headwinds, notably a 25% decline in core revenue and weaker PA and license receipts driven by customer inventory management and discontinued programs. Management reiterated full-year guidance while taking a conservative stance on additional 2026 milestones; they emphasized stability in the late-stage cell and gene therapy market, confidence in the pipeline, and expectations for core revenue growth later in the year. Overall, the results reflect transitionary near-term pressure but solid financial flexibility and promising product/partner catalysts that could drive recovery and growth over the medium term.View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
$4.00
Ownership Overview
3.01% Insiders
10.47% Mutual Funds
26.81% Other Institutional Investors
54.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---